Trial Profile
A phase 1/2 study combining ipilimumab with abiraterone acetate plus prednisone in chemotherapy- and immunotherapy-naive patients with progressive metastatic castration resistant prostate cancer
Status:
Active, no longer recruiting
Phase of Trial:
Phase I/II
Latest Information Update: 18 Sep 2023
Price :
$35
*
At a glance
- Drugs Ipilimumab (Primary) ; Abiraterone acetate; Prednisone
- Indications Adenocarcinoma; Prostate cancer
- Focus Adverse reactions; Therapeutic Use
- 11 Sep 2023 Planned End Date changed from 1 Sep 2023 to 1 Sep 2024.
- 11 Sep 2023 Planned primary completion date changed from 1 Sep 2023 to 1 Sep 2024.
- 09 Sep 2022 Planned End Date changed from 1 Sep 2022 to 1 Sep 2023.